VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Histopathological verification of glioblastoma     │ Histopathological verification of glioblastoma     │     100 │
│ multiforme (GBM: WHO grade IV) in remission (Group │ multiforme (GBM: WHO grade IV) in remission (Group │         │
│ A) or with active disease (Group B)                │ A) or with active disease (Group B)                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ CMV-positive GBM                                   │ CMV-positive GBM                                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ CMV seropositive                                   │ CMV seropositive                                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy 6 weeks or greater                 │ Life expectancy 6 weeks or greater                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Karnofsky/Lansky score 50 or greater               │ Karnofsky/Lansky score 50 or greater               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient or parent/guardian capable of providing    │ Patient or parent/guardian capable of providing    │     100 │
│ informed consent                                   │ informed consent                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Bilirubin less than 1.5x upper limit of normal,    │ Bilirubin less than 1.5x upper limit of normal,    │     100 │
│ AST less than 3x upper limit of normal, serum      │ AST less than 3x upper limit of normal, serum      │         │
│ creatinine less than 1.5x normal and Hgb 8.0 g/dL  │ creatinine less than 1.5x normal and Hgb 8.0 g/dL  │         │
│ or greater                                         │ or greater                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pulse oximetry of 90% or greater on room air       │ Pulse oximetry of 90% or greater on room air       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Sexually active patients must be willing to        │ Sexually active patients must be willing to        │     100 │
│ utilize one of the more effective birth control    │ utilize one of the more effective birth control    │         │
│ methods for 6 months after the CTL infusion. The   │ methods for 6 months after the CTL infusion. The   │         │
│ male partner should use a condom                   │ male partner should use a condom                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients should have been off other                │ Patients should have been off other                │     100 │
│ investigational antineoplastic therapy for one     │ investigational antineoplastic therapy for one     │         │
│ month prior to entry in this study                 │ month prior to entry in this study                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Informed consent explained to, understood by and   │ Informed consent explained to, understood by and   │     100 │
│ signed by patient/guardian. Patient/guardian given │ signed by patient/guardian. Patient/guardian given │         │
│ copy of informed consent                           │ copy of informed consent                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe intercurrent infection                      │ Severe intercurrent infection                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known HIV positivity                               │ Known HIV positivity                               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or lactating                              │ Pregnant or lactating                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of hypersensitivity reactions to murine    │ History of hypersensitivity reactions to murine    │     100 │
│ protein-containing products                        │ protein-containing products                        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Your personal trial has no unique criteria

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 100
Average Levenshtein Ratio of individual lines: 100.0
OverAll Ratio: 100.0
